Takeda Pharmaceutical Co. Ltd.

Takeda announced that Japan's Ministry of Health, Labour and Welfare approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults, making it the first and only medicine in Japan to address the underlying cause of the disease. ORZEYFUL is a first-in-class oral orexin receptor 2 agonist discovered in Takeda's Japanese laboratories, and the approval is based on Phase 3 FirstLight and RadiantLight studies showing significant improvements across the full range of NT1 symptoms compared to placebo. The most common adverse events were insomnia, urinary urgency, urinary frequency, and excessive saliva. This marks the third global approval for ORZEYFUL, following China and the United States, where the controlled substance classification is under review by the U.S. Drug Enforcement Administration. Takeda is proceeding with launch preparations in Japan.

Venture capitalist Vinod Khosla said artificial intelligence is rapidly expanding drug discovery, but traditional testing methods have failed to keep pace with the technology's progress. In a post on X, Khosla said AI has produced what he described as a 21st-century hyperabundance of potential new drugs and biological hypotheses, while drug testing still relies heavily on conventional animal studies. He argued that the industry needs a more human-relevant approach to evaluating potential treatments, pointing to Vivodyne, a biotechnology company developing technology to test drugs using living human tissues at scale. Khosla also said he was excited to continue working with Vivodyne as the company develops its Virtual Human data center, which he said could eventually help researchers predict how patients will respond to treatments. The article also noted that Anthropic launched Claude Science, an AI workbench for scientific research, Takeda reported its AI-developed psoriasis drug zasocitinib significantly outperformed Bristol-Myers Squibb's Sotyktu in a Phase 3 trial, and Nvidia and Eli Lilly announced a $1 billion AI co-innovation lab.

Takeda Pharmaceutical has received U.S. regulatory approval for ORZEYFUL to treat adult narcolepsy type 1, while also issuing new impairment guidance and reaffirming its fiscal 2027 earnings outlook. The stock trades at ¥5,582, with a 7-day return of 5.6% and a year-to-date return of 13.6%. One widely followed fair value estimate places the shares at ¥6,262.69, implying a 10.9% discount, while a separate discounted cash flow model suggests a fair value of ¥14,670.75, a 62% discount to the current price. The approval and guidance updates come as Takeda navigates the anticipated moderation of VYVANSE generic erosion after fiscal 2025, which is expected to allow core growth and launch products to drive a recovery in revenue and earnings.

Takeda has received U.S. FDA approval for ORZEYFUL, an oral orexin receptor 2 agonist, for the treatment of narcolepsy type 1 in adults. ORZEYFUL is the first and only medicine in the U.S. designed to address the underlying orexin deficiency that causes narcolepsy type 1, a rare neurological disorder affecting an estimated 120,000 people in the U.S. The approval was supported by data from the global Phase 3 FirstLight and RadiantLight studies, which showed significant improvements in excessive daytime sleepiness, cataplexy attacks, and overall patient function compared to placebo. Takeda expects ORZEYFUL to be available following the DEA scheduling process, anticipated within 90 days. Takeda's stock closed Wednesday at $16.72, up 0.97%, and rose to $17.16 in overnight trading.

AC Immune provided a corporate and financial update for the first half of 2026, reporting cash resources of CHF 75.4 million as of June 30, 2026, which are expected to fund operations into the fourth quarter of 2027. The company highlighted near-term clinical catalysts across its wholly-owned pipeline, including full results from Part 1 of the Phase 2 VacSYn trial of ACI-7104 in Parkinson's disease anticipated in the second half of 2026, supported by a $4 million grant from The Vijay and Marie Goradia Charitable Foundation. Initial data from the Phase 1 trial of ACI-19764, a brain-penetrant NLRP3 inhibitor, are also expected in the near future. Partnered programs generated milestone payments, including a $12 million payment from Takeda triggered by the initiation of the AD4 cohort in the ABATE trial of ACI-24 for Alzheimer's disease. Total revenues for the six months ended June 30, 2026 were CHF 16.2 million, up from CHF 2.3 million in the prior-year period, driven by milestone achievements under the amended Lilly agreement and Takeda arrangements. The net loss for the period was CHF 12.9 million, compared to CHF 40.2 million in the first half of 2025.

Takeda Pharmaceutical reported first-quarter fiscal 2026 results that were in line with its full-year outlook, as growth from core brands and newer products largely offset expected declines in its mature portfolio. Revenue totaled JPY 1.22 trillion, up 10.2% on an actual foreign-exchange basis but down 0.5% at constant exchange rates, while core operating profit was JPY 358.9 billion, rising 11.5% on an actual FX basis and declining 0.5% at constant exchange rates. Core inline brands, which represented 58% of total revenue, grew 2.3% at constant exchange rates, led by a 4% constant-currency increase for ENTYVIO, and new launches representing 4% of revenue grew 22.6% at constant exchange rates, supported by FRUZAQLA, LIVTENCITY, ADZYNMA and QDENGA. The company left its fiscal 2026 guidance unchanged and said it remains on track to generate JPY 650 billion to JPY 750 billion in free cash flow for the year. Takeda also highlighted preparations for three potential product launches: ORZEYFUL for narcolepsy type 1, rusfertide for polycythemia vera, and zasocitinib for psoriasis, with rusfertide receiving FDA priority review and an August PDUFA date.

Takeda Pharmaceutical posted higher revenue and operating profit in its consolidated results for the April–June 2026 quarter. The main driver was an expansion in overseas sales due to the weaker yen. The figures are based on International Financial Reporting Standards, though detailed numbers have not been disclosed.

Takeda Pharmaceutical announced new Phase 3 data for its oral TYK2 inhibitor zasocitinib in adults with moderate-to-severe plaque psoriasis, showing consistently high rates of skin clearance across difficult areas such as the scalp, nails, palms and soles compared with placebo. The results highlight zasocitinib's highly selective TYK2 inhibition as a potential way to tackle immune-mediated inflammation while aiming to limit safety issues associated with broader JAK inhibition. The data strengthen the case that immunology could become a more meaningful earnings pillar for Takeda, though the key short-term catalyst and risk still center on how efficiently the company converts multiple late-stage assets into approved, reimbursed products. The zasocitinib update fits alongside other recent late-stage wins, including positive Phase 3 results and Priority Review status for orexin agonist oveporexton in narcolepsy type 1, underscoring how much of the current pipeline story is tied to specialty CNS and immunology assets still moving through regulatory review. Takeda's narrative projects ¥4,858.7 billion revenue and ¥364.5 billion earnings by 2029, requiring 2.5% yearly revenue growth and an earnings increase of about ¥516.9 billion from -¥152.4 billion today, while some analysts assume revenues of about ¥5,072.4 billion and earnings near ¥423.0 billion by 2029.

On the 24th, the Nikkei Average opened lower, falling 838.35 yen to 65,584.25 yen. The sharp continued decline of major indices in the US stock market the previous day weighed on sentiment, while rising crude oil prices due to escalating tensions in the Middle East and an increase in domestic long-term interest rates also capped stocks. Meanwhile, although the yen weakened to the 163.80 range against the dollar and there were expectations for the full-fledged start of April-June earnings announcements from major domestic companies, selling dominated at the open. Among the top traded issues on the Tokyo Stock Exchange Prime Market, Disco, SoftBank Group, and Advantest declined, while Takeda Pharmaceutical and INPEX rose.

Takeda Pharmaceutical announced that its dengue vaccine Qdenga has been approved by India's drug regulatory authority. This marks the first approval of a dengue vaccine in India, and Takeda indicated plans to launch it in the first half of 2027, initially making it available through private healthcare providers. Qdenga has now been approved in 43 countries, and in late-stage clinical trials it showed 80.2 percent efficacy against dengue cases one year after the second dose, and 90.4 percent efficacy against hospitalization at 18 months. Takeda has contracted production to Indian vaccine maker Biological E, and this partnership enables a maximum annual production capacity of 50 million doses, putting the company on track toward its goal of having a global manufacturing capacity of 100 million doses per year by 2030.

Nvidia CEO Jensen Huang unveiled a broad slate of AI products, partnerships, and customer deployments at the company's Japan AI event in Tokyo on July 15. The announcements spanned physical AI, healthcare, financial services, quantum computing, automotive, manufacturing, and gaming, highlighting Nvidia's push to position its technologies at the forefront of Japan's next-generation AI infrastructure. In physical AI and robotics, Nvidia launched Cosmos 3 Edge for on-device vision reasoning, and companies including FANUC, Fujitsu, Hitachi, Kawasaki Heavy Industries, Kubota, NEC, SoftBank, Sony Group, and Yaskawa Electric plan to join the Nvidia Cosmos Coalition to develop open physical AI models. In healthcare, Astellas Pharma, Eisai, Daiichi Sankyo, Ono Pharmaceutical, and Takeda Pharmaceutical are deploying Nvidia BioNeMo for AI-powered drug discovery, while Canon and Fujifilm introduced Nvidia-powered next-generation CT systems, and Kawasaki Heavy Industries is advancing AI-enabled surgical and hospital robots. In financial services, Mizuho Financial plans Japan's largest on-premises AI factory for banking, Sumitomo Mitsui Financial has deployed an AI factory through Japan Research Institute, and Rakuten Bank is developing AI transaction foundation models using Nvidia Agent Toolkit. Huang emphasized that the next wave of AI will be physical AI—robots, factories, vehicles, and industrial systems that can perceive, reason, and act in the real world—and said Japan's leadership in robotics, manufacturing, and precision engineering positions it to play a leading role in this transition.

The global Von Willebrand disease market is recording steady growth as awareness of inherited bleeding disorders increases and access to advanced diagnostics and therapies expands. Demand for desmopressin, antifibrinolytic agents and replacement therapies remains a key market driver, while progress in molecular diagnostics and next-generation sequencing is enabling more precise disease classification and treatment planning. Therapeutic advances, including Takeda’s recombinant Von Willebrand factor product Vonvendi and Octapharma’s plasma-derived Wilate, continue to enhance treatment options for eligible patients. Government funding for rare disease programs and improved reimbursement coverage are also contributing to wider access. However, underdiagnosis remains a significant challenge, particularly in regions with limited specialist care and diagnostic infrastructure, and variable treatment response, the cost of biologic therapies and complex regulatory requirements can restrict patient access and delay commercialization. Innovation in gene therapy, extended half-life Von Willebrand factor products and precision medicine could help address these unmet needs, while AI-enabled diagnostics, digital health platforms and remote patient monitoring are expected to play a larger role in disease management.

Takeda Pharmaceutical and the Indonesian Government have launched a landmark collaboration to build the country’s plasma ecosystem and secure sustainable access to plasma-derived medicinal products. The multi-year initiative, marked by a fractionation license granted to Takeda by the Ministry of Health, is the first of its kind in the ASEAN region. As part of the initial phase, Takeda will invest up to $30 million over a two-year pilot program to establish a network of high-quality plasma donation centers starting in 2027. The facilities will integrate into Takeda’s global BioLife network, adhering to strict international regulatory standards, and while local centers scale up, plasma collected in Indonesia will be processed across Takeda’s global manufacturing footprint with priority allocation directed back to meet Indonesian domestic healthcare needs. Beyond the initial pilot, Takeda and the government will assess the feasibility of constructing a state-of-the-art plasma manufacturing facility in Indonesia to feed both regional and global supply chains.

Protagonist Therapeutics shares have surged 64% over the past six months, far outpacing the industry's 4.5% gain, driven by advances in its rare hematology candidate rusfertide and the approval of partnered therapy Icotyde. The FDA accepted the rusfertide new drug application with priority review and set an August 2026 target action date, while Protagonist restructured its deal with Takeda to receive a $400 million upfront payment, a $75 million approval milestone, up to $775 million in sales milestones, and tiered royalties of 14% to 29% on global sales. Separately, the FDA approved Icotyde, an oral IL-23 receptor inhibitor co-developed with Johnson & Johnson, for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment and leaving Protagonist eligible for up to $580 million in additional milestones plus tiered royalties of 6% to 10% on net sales. The company is also advancing wholly owned pipeline assets, including an oral IL-17 antagonist expected to enter phase II in 2026.

The innovative drug sector has staged a strong rebound after an earlier correction, with the SSE STAR Market Biomedical Index rising 1.10%. In the first half of 2026, the total value of China's out-licensing deals approached 100 billion US dollars, and Chinese pharmaceutical companies occupied eight of the top ten global pharmaceutical transactions, indicating that the trend of innovative drugs going overseas remains robust. Guosheng Securities noted that domestic innovative drugs continue to see active external collaborations, and platform-based technological capabilities are gaining broad recognition from overseas multinational corporations. Landmark deals such as Insilico Medicine with Takeda and CSPC Pharmaceutical Group with AstraZeneca signal that Chinese pharmaceutical companies are upgrading from single-product licensing to the out-licensing of underlying technology platforms. The Sci-Tech Innovation Board Healthcare ETF Harvest closely tracks the SSE STAR Market Biomedical Index, which selects 50 large-cap biomedical industry leaders from the STAR Market, with the top ten constituents accounting for a combined weight of 51.84%.

Insilico Medicine has entered into a strategic collaboration with Takeda Pharmaceutical to advance novel drug candidates across Takeda's therapeutic areas. The partnership will leverage Insilico's proprietary Pharma.AI platform to identify clinically differentiated molecules, with Insilico leading AI-driven discovery and Takeda handling clinical validation and global development. Financial terms include approximately $60 million in upfront and near-term payments to Insilico, with success-based milestones that could bring the total deal value to about $600 million, plus tiered royalties on future sales. Takeda will hold exclusive worldwide rights to develop, manufacture, and commercialize any resulting therapeutics.

Takeda Pharmaceutical announced positive topline results from its Phase 3 LATITUDE Atlas study, showing its investigational oral TYK2 inhibitor zasocitinib outperformed deucravacitinib on the primary endpoint of PASI 100 response rates at Week 16 in adults with moderate-to-severe plaque psoriasis. The therapy also met all major secondary endpoints, including PASI 90 and Static Physician's Global Assessment 0 responses, while maintaining a favorable safety profile with no new concerns. The global trial enrolled 606 participants across eight countries. Separately, the U.S. FDA accepted Takeda’s supplemental Biologics License Application for intravenous ENTYVIO for pediatric patients aged 2 years and older with moderately to severely active ulcerative colitis and Crohn’s disease, with a target action date in the first quarter of 2027.

This week brought a mix of FDA and EU approvals, layoffs, acquisitions, and clinical trial updates across the biotech sector. Ionis Pharmaceuticals secured FDA approval for TRYNGOLZA as an adjunct therapy for severe hypertriglyceridemia, while Merck received European Commission approval for Keytruda in combination with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer. Gilead's Trodelvy was cleared by the FDA for first-line metastatic triple-negative breast cancer, and Pfizer's IBRANCE won expanded approval for HR+/HER2+ metastatic breast cancer. Natera gained Japanese approval for its Signatera MRD test in colorectal cancer, and AbbVie's MAVIRET was approved in the EU for both acute and chronic Hepatitis C. Achieve Life Sciences received an FDA Complete Response Letter for its Cytisinicline NDA due to manufacturing deficiencies, though no efficacy or safety issues were raised. ADC Therapeutics announced a 17% workforce reduction as part of a strategic reorganization to focus on its ZYNLONTA lymphoma franchise. In dealmaking, Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, representing an enterprise value of $11.3 billion, while Ionis inked a licensing deal with Recordati for Zilganersen, an investigational therapy for Alexander disease. Passage Bio and Remix Therapeutics entered an all-stock merger agreement, and Boundless Bio and Serapha Bio also announced an all-stock merger. On the clinical front, IMUNON's Phase 3 OVATION 3 trial passed a safety review, Takeda's Zasocitinib showed superiority over Deucravacitinib in a Phase 3 psoriasis study, and Eledon reported positive long-term kidney transplant data for Tegoprubart. However, Pfizer's Sigvotatug vedotin missed its primary overall survival endpoint in a Phase 3 non-small cell lung cancer study, and MapLight's ML-004 failed to meet its primary endpoint in autism spectrum disorder, though it showed an irritability signal in adolescents. Definium Therapeutics reported positive Phase 3 results for DT120 ODT in major depressive disorder.

The IgA nephropathy clinical trial space is intensifying, with more than 25 companies actively developing over 30 pipeline drugs, according to a new report from DelveInsight. Key players include Haisco Pharmaceutical Group, Novartis, Vertex Pharmaceuticals, Biogen, Vera Therapeutics, AstraZeneca, Roche, Ionis Pharmaceuticals, Takeda, Arrowhead Pharmaceuticals, and others. Promising therapies in various trial phases include HSK39297, Zigakibart, Povetacicept, Felzartamab, Atacicept, ULTOMIRIS, Sefaxersen, TAK-079, ARO-C3, NM8074, WAL0921, KP104, PS-002, BHV-1400, CM313, NTQ5082, RNK288, and IFX 301. Approximately 12 or more drugs are in late-stage development, targeting mechanisms such as Complement Factor B inhibition, BAFF and APRIL antagonism, antibody-dependent cell cytotoxicity, Gd-IgA1 degradation, RNA interference, and CD38 antagonism. Recent milestones include positive Phase III data for Povetacicept and Atacicept, and publication of telitacicept results in the New England Journal of Medicine.

Takeda has appointed Julie Kim as its new Representative Director, President and Chief Executive Officer, completing an 18-month leadership transition. Shareholders elected Kim as an internal director at the company's 150th Annual General Meeting of Shareholders in Osaka, Japan, and the Board of Directors subsequently named her to the top role, effective June 24, 2026. Former President and CEO Christophe Weber retired from the company and the Board after 12 years of service. The Board also added three new external directors: Bruce Broussard, Koichiro Kimura, and Dr. Paul Stoffels, bringing the total number of external directors to eight out of 11 members. Takeda highlighted plans for three major product launches in the next 12 months and a pipeline of five additional late-stage assets as it enters its next growth phase.

Takeda announced that its investigational oral drug zasocitinib demonstrated statistical superiority over deucravacitinib in a Phase 3 head-to-head study for moderate-to-severe plaque psoriasis. More than 35% of zasocitinib-treated patients achieved complete skin clearance, or PASI 100, at week 16, which is more than 2.5 times the response rate for deucravacitinib. The study, called LATITUDE Atlas, enrolled 606 participants across eight countries and met all primary and key secondary endpoints, including PASI 90 and sPGA 0. The safety profile was consistent with previous studies and no new safety signals were identified. Takeda plans to submit a New Drug Application to the US FDA and other regulators starting this fiscal year.

Boltz PBC has announced a collaboration with Takeda to deploy its proprietary biomolecular AI models and platform across Takeda's Research organization. The partnership will give Takeda scientists access to Boltz's latest foundation models, including BoltzMol-1 and BoltzProt-1, for structure prediction, affinity estimation, and generative design. Takeda teams will use the Boltz platform through the Boltz Lab interface and Boltz API, which can integrate with large language model agents for natural-language-driven workflows. Boltz scientists will also work with Takeda on selected programs to fine-tune models for specific targets, while Takeda retains ownership of any compounds generated. The collaboration aims to make AI a practical part of everyday drug discovery, supporting more efficient advancement of high-quality programs.

The chronic inflammatory demyelinating polyneuropathy treatment market is projected to grow positively by 2036 across leading markets, driven by an expanding diagnosed patient population, improved disease awareness, and the anticipated introduction of novel mechanism-based therapies. The United States accounted for the largest market size in 2025 compared with the EU4 countries, the United Kingdom, and Japan. Key companies advancing new treatments include Sanofi, Immunovant, argenx, Nuvig Therapeutics, Dianthus Therapeutics, and Takeda, with promising pipeline therapies such as Riliprubart, Batoclimab, Empasiprubart, NVG-2089, DNTH103, TAK-881, and TAK-411. The prevalence of CIDP is estimated at around 5 to 7 cases per 100,000 individuals in the UK, and the market is seeing increased demand for targeted and long-acting therapies including subcutaneous immunoglobulin formulations and FcRn inhibitors.